Clinical assessments were conducted every 3 months to evaluate efficacy, measured as percentage of total weight loss (%TWL), excess weight loss (%EWL), changes in BMI, and improvement in comorbidities, as well as tolerance, monitored for adverse effects including gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) and discontinuation rates
Females may require lower doses than males to achieve the desired effects
This study provided data with a longer duration of follow-up compared with previous cohort studies
[34] An additional family utilizing an iron cofactor (FeSOD) has also been identified, which is evolutionarily related to MnSOD (Wolfe-Simon et al
The mechanisms are different